logo

Meiragtx Holdings Plc (MGTX)



Trade MGTX now with
  Date
  Headline
10/3/2020 12:48:20 PM MeiraGTx Presents 9-Month Data From Phase 1/2 Trial Of AAV-RPGR At EURETINA 2020 Virtual Congress
9/10/2019 8:36:36 AM MeiraGTx To Present Clinical Data From Phase 1/2 Trial Of AAV-RPE65 At Upcoming Scientific Conferences
5/14/2019 7:34:56 AM MeiraGTx Announces Positive 6-Month Data From Phase 1/2 Trial Of AAV-RPE65 For RPE65-Deficiency
5/10/2019 8:34:42 AM MeiraGTx Appoints Nicole Seligman To Board Of Directors
1/31/2019 6:36:52 AM Janssen Enters Agreement With MeiraGTx To Develop Gene Therapy Programs For Inherited Retinal Diseases
1/31/2019 6:33:40 AM MeiraGTx Enters Broad Strategic Collaboration With Janssen
10/31/2018 8:37:39 AM EiraGTx In Licensing Deal With NIDCR For Gene Therapy Treatment For Sjögren Syndrome And Associated Xerostomia
10/9/2018 7:05:41 AM MeiraGTx Buys Vector Neurosciences In All-stock Transaction, Gains Phase 2 Gene Therapy Program For Parkinson’s Disease
8/27/2018 8:04:50 AM MeiraGTx Announces AAV-CNGA3 Granted Rare Pediatric Disease Designation By FDA For Achromatopsia
8/20/2018 8:05:32 AM MeiraGTx Announces AAV-CNGB3 Granted Fast Track Designation By FDA For Treatment Of Achromatopsia
8/13/2018 7:05:48 AM MeiraGTx Says FDA Granted Orphan Drug Designation For AAV-CNGA3 Gene Therapy Product Candidate
8/8/2018 8:09:03 AM MeiraGTx Holdings Q2 Net Loss $30 Mln Or $2.29/Shr Vs Loss $7.2 Mln Or $0.85/Shr Last Year
6/26/2018 8:08:52 AM MeiraGTx Gets Positive Opinion For Orphan Drug Designation In EU For AAV-CNGA3 For Treatment Of Achromatopsia